Centanafadine, a new ADHD medication, has been approved in the US, offering a novel approach to treating attention-deficit hyperactivity disorder. This once-a-day tablet, sold under the brand name Simtriyo, targets three neurotransmitters: noradrenaline, dopamine, and serotonin, setting it apart from traditional ADHD drugs. While it's been hailed as a non-stimulant by its developer, the US FDA labels it as a stimulant, highlighting the ongoing debate in the field. This article delves into the unique mechanisms of centanafadine, its potential advantages, and the challenges in comparing it to existing ADHD medications. It also explores the side effects and the reasons behind its unavailability in Australia, shedding light on the complexities of ADHD treatment and the ongoing quest for effective therapies.
